Literature DB >> 25769098

De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system.

Ahmed Abdel-Razik1, Nasser Mousa, Rania Elhelaly, Ahmed Tawfik.   

Abstract

BACKGROUND AND OBJECTIVES: Portal vein thrombosis (PVT) is a potential lethal complication in late liver cirrhosis. There is a lack of knowledge of the clinical features and risk factors of PVT. We aimed to investigate the clinical and radiological characteristics, and biochemical markers of cirrhotic patients to determine the high-risk individuals for PVT attending our center. PATIENTS AND METHODS: Of 426 cirrhotic patients, only 120 consecutive patients were included. Clinical, biochemical, immunological, Model for End-stage Liver Disease (MELD) score, portal vein patency, and flow velocity were measured in all patients at baseline and every 6 months thereafter. Variables that could predict the development of PVT within 1 year were identified by multiple logistic regression.
RESULTS: Only 95 patients completed the study; PVT was found in 17 (17.9%) patients. PVT was observed mainly in the portal trunk, superior mesenteric vein, and splenic vein. Univariate analysis showed that diabetes mellitus, lower levels of hemoglobin, platelet counts, and portal vein flow velocity as well as increased MELD scores, platelet indices, portal vein diameter, and splenic thickness were associated with PVT patients than in non-PVT patients (all P<0.01).
CONCLUSION: The incidence of PVT was 17.9%. PVT occurred mainly in the portal vein trunk, superior mesenteric vein, and splenic vein. Diabetes mellitus, lower levels of hemoglobin, platelet count and portal vein flow velocity as well as increased MELD score, platelet indices, portal vein diameter, and splenic thickening were associated with PVT. Splenic thickening, marked reduced of mean portal flow velocity, and diabetes mellitus may be risk factors for PVT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25769098     DOI: 10.1097/MEG.0000000000000325

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  20 in total

Review 1.  Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.

Authors:  Xiangbo Xu; Xiaozhong Guo; Valerio De Stefano; Gilberto Silva-Junior; Hemant Goyal; Zhaohui Bai; Qingchun Zhao; Xingshun Qi
Journal:  Hepatol Int       Date:  2019-06-07       Impact factor: 6.047

2.  Predictive Effect of Mean Platelet Volume in Patients with Portal Vein Thrombosis: A Meta-analysis of Case-control Studies.

Authors:  Wen-Yi Lin; Xuan Lu; Feng-Juan Fan; Yu Hu
Journal:  Curr Med Sci       Date:  2018-08-20

3.  Rebalanced hemostasis in liver disease: a misunderstood coagulopathy.

Authors:  Lara N Roberts
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Metabolic Disorders and Risk of Portal Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Jiao Li; Qiong Wang; Mei Yang; Xiaobin Sun
Journal:  Turk J Gastroenterol       Date:  2022-07       Impact factor: 1.555

Review 5.  Pre-transplant portal vein thrombosis in non-alcoholic fatty liver disease patients-pathogenesis, risk factors, and implications on management.

Authors:  Peter DeLeeuw; Uchenna Agbim
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

6.  Research on Portal Venous Hemodynamics and Influencing Factors of Portal Vein System Thrombosis for Wilson's Disease after Splenectomy.

Authors:  Zhou Zheng; Qingsheng Yu; Hui Peng; Wanzong Zhang; Yi Shen; Hui Feng; Long Huang; Fuhai Zhou; Qi Zhang; Qin Wang
Journal:  Front Surg       Date:  2022-05-30

Review 7.  Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai).

Authors: 
Journal:  J Dig Dis       Date:  2021-03-07       Impact factor: 2.325

8.  Long-term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients.

Authors:  Haibo Chu; Wei Han; Lei Wang; Yongbo Xu; Fengguo Jian; Weihua Zhang; Tao Wang; Jianhua Zhao
Journal:  BMC Surg       Date:  2015-07-24       Impact factor: 2.102

9.  Antioxidant, antidiarrheal, hypoglycemic and thrombolytic activities of organic and aqueous extracts of Hopea odorata leaves and in silico PASS prediction of its isolated compounds.

Authors:  Mohammad Shah Hafez Kabir; Mohammed Munawar Hossain; Md Imtiazul Kabir; Shabbir Ahmad; Nishan Chakrabarty; Md Atiar Rahman; Md Mominur Rahman
Journal:  BMC Complement Altern Med       Date:  2016-11-21       Impact factor: 3.659

Review 10.  Anticoagulation in cirrhosis: a new paradigm?

Authors:  Filippo Leonardi; Nicola De Maria; Erica Villa
Journal:  Clin Mol Hepatol       Date:  2017-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.